Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...

Renal Drug Excretion: Tubular Secretion

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Drug Elimination by Renal Route: Tubular Secretion

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...

Drug Elimination by Renal Route: Tubular Reabsorption

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026

Same author

Efficacy of larotrectinib in pediatric cancers with <i>NTRK</i> gene fusions.

Translational pediatrics·2026

Same author

Neddylation inhibition induces DNA double-strand breaks, hampering tumor growth in vivo, and promotes radiosensitivity in PAX3-FOXO1 rhabdomyosarcoma.

Cell death discovery·2025

Same author

Rhabdomyosarcoma: development of molecular therapeutics under the microscope.

Expert opinion on therapeutic targets·2025

Same author

MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD.

iScience·2025

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Everolimus.

Peter J Houghton¹

¹Center for Childhood Cancer, The Research Institute, Nationwide Children's Hospital, Columbus, Ohio 43205, USA. Peter.Houghton@nationwidechildrens.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research

|February 25, 2010

Summary

Everolimus, a rapamycin analog, is approved for advanced renal cell carcinoma (RCC). It improves progression-free survival (PFS) by inhibiting the mammalian target of rapamycin (mTOR) pathway, though its precise antitumor mechanisms require further study.

Area of Science:

Oncology
Pharmacology

Background:

Renal cell carcinoma (RCC) is a complex malignancy.
Vascular endothelial growth factor (VEGF) receptor signaling inhibitors are a standard treatment for advanced RCC.
Everolimus, an orally administered rapamycin analog, targets the mammalian target of rapamycin (mTOR) pathway.

Purpose of the Study:

To review the mechanism of action of everolimus in renal cell carcinoma.
To summarize preclinical and clinical antitumor activity of everolimus against RCC.
To discuss the role of everolimus in patients with RCC refractory to VEGF receptor signaling inhibitors.

Main Methods:

Literature review of preclinical studies and clinical trials involving everolimus for RCC.
Analysis of data on progression-free survival (PFS) and tumor response.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Experiment Videos

Last Updated: Jun 15, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Discussion of the established target (mTOR) and proposed mechanisms of action.

Main Results:

Everolimus significantly increased progression-free survival (PFS) in RCC patients compared to placebo (4.0 vs 1.9 months).
Tumor regressions were infrequently observed with everolimus treatment.
The precise mechanisms by which everolimus retards tumor growth are not fully elucidated.

Conclusions:

Everolimus demonstrates clinical activity in advanced RCC, particularly in patients refractory to VEGF inhibitors.
Further research is needed to fully define the antitumor mechanisms of everolimus.
Identification of biomarkers to predict everolimus sensitivity in RCC remains an important goal.